Retroviral targeting of proliferating endothelial cells

• Autorzy: Gornikiewicz A. , Zommer A. , Jakesz R. , Gnant M. , Brostjan C.
• Języki publikacji: EN

Abstrakty

EN

Tumor growth requires the formation of new blood vessels by endothelial cells. Thus, surface molecules - such as angiogenin receptors - that are selectively expressed on growing endothelium represent an attractive target for directed delivery of compounds to tumor tissue. We attempted to obtain genetically engineered retroviral vectors targeted to the endothelium by inserting the human angiogenin sequence into Moloney murine leukemia virus envelope glycoprotein. Abundant expression of the chimeric protein could be verified. However, while being selective for proliferating human endothelial cells, the recombinant retroviral particles displayed low transduction efficiencies and thus have to be further improved.

Słowa kluczowe

EN

angiogenin; retrovirus; targeting; formation; envelope glycoprotein; endothelial cell; tumour growth; new blood vessel

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2005
• Tom: 52
• Numer: 3
• Opis fizyczny: p.731-735,fig.,ref.

Twórcy

autor

Gornikiewicz A.

• Medical University of Vienna, Vienna, Austria

autor

Zommer A.

autor

Jakesz R.

autor

Gnant M.

autor

Brostjan C.

Bibliografia

• Cosset FL, Morling FJ, Takeuchi Y, Weiss RA, Collins MK, Russell SJ (1995) J Virol 69: 6314–6322.
• Folkman J (1971) N Engl J Med 285: 1182–1186.
• Hall FL, Gordon EM, Wu L, Zhu NL, Skotzko MJ, Starnes VA, Anderson WF (1997) Hum Gene Ther 8: 2183–2192.
• Han X, Kasahara N, Kan YW (1995) Proc Natl Acad Sci USA 92: 9747–9751.
• Hu GF, Strydom DJ, Fett JW, Riordan JF, Vallee BL (1993) Proc Natl Acad Sci USA 90: 1217–1221.
• Hu GF, Riordan JF, Vallee BL (1997) Proc Natl Acad Sci USA 94: 2204–2209.
• Karavanas G, Marin M, Salmons B, Gunzburg WH, Piechaczyk M (1998) Crit Rev Oncol Hematol 28: 7–30.
• Kasahara N, Dozy AM, Kan YW (1994) Science 266: 1373– 1376.
• Khare PD, Shao Xi L, Kuroki M, Hirose Y, Arakawa F, Nakamura K, Tomita Y (2001) Cancer Res 61: 370–375.
• Klump H, Schiedlmeier B, Vogt B, Ryan M, Ostertag W, Baum C (2001) Gene Ther 8: 811–817.
• Konishi H, Ochiya T, Chester KA, Begent RH, Muto T, Sugimura T, Terada M (1998) Hum Gene Ther 9: 235–248.
• Li R, Riordan JF, Hu G (1997) Biochem Biophys Res Commun 238: 305–312.
• Liu L, Anderson WF, Beart RW, Gordon EM, Hall FL (2000) J Virol 74: 5320–5328.
• Miller DG, Edwards RH, Miller AD (1994) Proc Natl Acad Sci USA 91: 78–82.
• Montero S, Guzman C, Cortes Funes H, Colomer R (1998) Clin Cancer Res 4: 2161–2168.
• Pear WS, Nolan GP, Scott ML, Baltimore D (1993) Proc Natl Acad Sci USA 90: 8392–8396.
• Schnierle BS, Moritz D, Jeschke M, Groner B (1996) Gene Ther 3: 334–342.
• Somia NV, Zoppe M, Verma IM (1995) Proc Natl Acad Sci USA 92: 7570–7574.
• Thorpe PE, Burrows FJ (1995) Breast Cancer Res Treat 36: 237–251.
• Wang H, Kavanaugh MP, North RA, Kabat D (1991) Nature 352: 729–731.
• Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM, Kovesdi I (1996) J Virol 70: 6831–6838.
• Wickham TJ, Haskard D, Segal D, Kovesdi I (1997) Cancer Immunol Immunother 45: 149–151.
• Wu BW, Lu J, Gallaher TK, Anderson WF, Cannon PM (2000) Virology 269: 7–17.
• Zavorotinskaya T, Albritton LM (2001) Mol Ther 3: 323–328